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Recently, several microRNAs (miRNAs) have been reported as promising biomarkers for cancer detection and 
tumor recurrence risk. Due to its stability, miRNA can be accessed from samples stored in severe conditions, 
such as feces or formalin-fixed paraffin-embedded (FFPE) tissue. Fecal miRNA extracted from the residuum of 
fecal occult blood tests (FOBTs) was assessed to determine whether a combination of this fecal miRNA test 
(FmiRT) with FOBT could improve the false-negative rate of colorectal cancer (CRC) screening compared with 
FOBT alone. Expression of miR-106a in patients with both positive and negative FOBTs was significantly higher 
than in healthy volunteers. To identify a high-risk group for recurrence, miRNAs were extracted from FFPE 
samples of patients with stage II CRC. Tumor recurrence occurred at a significantly higher rate in patients with 
increased miR-181c expression than in those with lower expression. The recurrence rate in patients with stage II 
CRC with higher expression of miR-181c was similar to that of patients with stage III CRC who had been 
treated by surgical resection alone. As miRNAs are stable in several severe storage conditions, such as in fecal 
and FFPE samples, they could be valuable, accessible biomarkers for CRC, for use both in cancer screening and 
as predictors of recurrence. 
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Introduction 
Colorectal cancer (CRC) is the second highest cause of 
cancer-related mortality worldwide [1]. Patients with CRC 
have a much better chance of recovery with early detection 
and resection at an early stage. Thus, screening is important 
to reduce mortality. Indeed, the widespread adoption of the 
fecal occult blood test (FOBT) as a CRC screening test has 
enabled CRC incidence and mortality rates to decline for 2 
decades [2-4]. During the past decade, disease-free survival 
among patients with advanced stage CRC has improved 
significantly, due to the introduction of adjuvant 
chemotherapy [5]. However, this therapeutic success has not 
been observed in patients with early stage CRC. The lack of 
simple and reliable relapse risk markers for patients with 
early stage CRC makes it difficult to identify patients in 
whom the hazards of adjuvant chemotherapy may be offset 
by benefits with respect to disease-specific survival [5]. 
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MicroRNAs (miRNAs), which are small (18–25 nt) 
noncoding RNA molecules, regulate the function of specific 
mRNAs and play various roles in cancer progression. The 
function of miRNAs is to downregulate the expression of 
multiple target genes by degrading their corresponding 
mRNA, blocking gene expression via RNA interference [6, 7]. 
As of June 2014, a total of 2661 human mature miRNAs had 
been bioinformatically reported in miRBase 21 [8]. The high 
stability of miRNAs means that they can be preserved in 
poor conditions, such as fecal samples [9] and formalin-fixed 
paraffin-embedded (FFPE) sections stored for decades [10]. 
Several studies have suggested that miRNAs could be 
useful for the diagnosis of CRC using RNA extracted from 
feces [11-13], and could represent potential biomarkers for 
CRC recurrence in tissue samples [14, 15]. In addition, recent 
studies have demonstrated that several miRNAs play 
important roles in tumor invasion and metastasis [16, 17]. Thus, 
miRNAs, which can be readily analyzed from samples in 
severe storage conditions, are worthy of investigation as 
tumor biomarkers for CRC screening and recurrence. 
Fecal miRNA test to detect false negative FOBT results 
Several large-scale studies have demonstrated the low 
sensitivity of the FOBT, which can cause false-negative 
results in some patients with CRC, and false-positives in 
some healthy individuals [18-21]. Several attempts to use 
DNA- [22, 23] or RNA-based molecular biological methods 
[24-26] for the early detection of CRC have been reported. 
However, these methods have not proved superior to the 
FOBT in terms of sensitivity and specificity. However, 
several studies have suggested that miRNA directly extracted 
from feces could be useful for the diagnosis of CRC [11-13].  
In our previous study, miRNA extracted from the 
residuum of FOBTs was assessed in a fecal miRNA test 
(FmiRT) to determine whether combining the FmiRT and the 
FOBT could improve the rate of false-negatives in CRC 
screening compared with the FOBT alone [27]. Fecal miRNA 
of sufficient quality for real-time reverse 
transcription-polymerase chain reaction (RT-PCR) analysis 
was extracted from the residuum of FOBTs stored at 4°C for 
up to 5 days [28], and significant positive correlations were 
observed between miRNAs extracted from feces and those 
extracted from the residuum of FOBT [27]. Chang et al. 
reported that several miRNAs showed high expressional 
correlations between tissue, plasma, and stool [29]. This 
indicates that such miRNAs might be clinically applicable 
for CRC detection. 
Significant differences in the relative expression levels of 
9 selected miRNAs were observed between patients with 
CRC and healthy volunteers (P < 0.05). In particular, 
miR-106a expression was significantly higher in both 
positive and negative FOBT patients than in healthy 
volunteers (P = 0.001). The sensitivity and specificity of the 
FmiRT using miR-106a expression were 34.2% and 97.2%, 
and those of the FOBT were 60.7% and 98.1%, respectively. 
The overall sensitivity and specificity of the new combined 
screening method were 70.9% and 96.3%, respectively. One 
quarter of patients with CRC with false-negative FOBTs 
were identified as true positives by the addition of the FmiRT 
using fecal miR-106a [27].  
Those findings suggest that miR-106a is a promising 
molecular marker to identify patients with CRC with 
false-negative FOBT results. Combined FmiRT/FOBT 
screening might improve the sensitivity of CRC detection. 
Using miRNA as a predictive marker of recurrence in 
stage II CRC 
The standard treatment for stages I–III CRC is surgical 
resection. The effectiveness of adjuvant chemotherapy for 
patients with stage III CRC has been demonstrated [30, 31]. 
However, the effectiveness of adjuvant chemotherapy for 
patients with stage II CRC has not been established to date. 
However, the recurrence rates of patients with stage II CRC 
who undergo surgery alone are 12%–37% [32-36]. According 
to the guidelines of the American Society of Clinical 
Oncology [37] and the European Society for Medical 
Oncology [38], high-risk patients with stage II CRC are 
defined by clinicopathological factors. However, there are no 
robust biomarkers suitable for predicting recurrence in 
patients with stage II CRC. To identify patients with stage II 
CRC who would benefit from adjuvant chemotherapy, the 
identification of adequate biomarkers would be an important 
advancement in clinical settings. 
To identify biomarkers to predict the recurrence of stage II 
CRC, miRNAs extracted from the tissue samples of patients 
with stage II CRC who had undergone surgical resection 
were assessed [39]. Initially, miRNAs that were expressed at 
higher levels in cancer tissues compared to normal tissues 
were identified using a highly sensitive miRNA microarray. 
Of 1719 miRNAs, 105 showed significantly greater 
expression in cancer tissues than in normal tissues (P < 0.01). 
Among the 105 miRNAs, 15 showed significantly higher 
expression in patients with recurrence than in those without 
recurrence (P < 0.05). The expression of the 15 candidate 
miRNAs was analyzed. In a univariate analysis, tumor 
recurrence occurred at significantly higher rates in patients 
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with increased expression of let-7a, -7d, -7e, miR-23c, -26b, 
-128a, -151-5p, and -181c; a tumor depth of T4; and
mucinous carcinoma histological type (P < 0.05). In a
multivariate analysis including pathological factors,
increased expression of miR-181c was an independent
predictive factor of recurrence [odds ratio (OR): 9.43, 95%
confidence interval (CI): 2.57–34.48, P = 0.001], and also an
independent predictive factor of worse relapse-free survival
(RFS) [hazard ratio (HR): 6.62, 95% CI: 2.08–21.28, P =
0.001].
However, it is difficult to obtain frozen tissues and to store 
them long term. Fortunately, miRNAs are preserved in poor 
conditions, even detectable in FFPE sections stored for 20 
years [10]. Thus, FFPE tissues were analyzed in comparison 
with their corresponding frozen tissues in the same cohort. In 
a univariate analysis, tumor recurrence occurred at 
significantly higher rates in patients with increased 
expression of let-7d, -7e, miR-26b, -128a, -148b, -151-5p, 
and -181c; a tumor depth of T4; and mucinous carcinoma 
histological type (P < 0.05). Interestingly, the increased 
expression of miR-181c was also an independent predictive 
factor of recurrence [OR: 7.46, 95% CI: 1.97–28.57, P = 
0.003], and an independent predictive factor of worse RFS 
[HR: 4.74, 95% CI: 1.66–13.51, P = 0.001] in a multivariate 
analysis. 
Since the miRNA expression analysis showed similar 
results between frozen and FFPE tissues in the cohort, 
another cohort with patients with stage II CRC who had 
undergone surgical resections were enrolled to validate the 
analysis using frozen tissues and FFPE tissues. The 
expression of miR-181c extracted from FFPE cancer tissues 
was analyzed. In the validation cohort, tumor recurrence 
occurred at a significantly higher rate in patients with higher 
miR-181c expression than in those with lower expression (P 
= 0.001). Moreover, the RFS was significantly worse for 
patients with higher miR-181c expression than for those with 
lower miR-181c expression (P < 0.001). 
In a combined analysis using FFPE tissues from the two 
cohorts, the recurrence rates were 42.9% and 8.3% with 
higher and lower expression of miR-181c, respectively 
(Figure 1). The recurrence rate in patients with stage II CRC 
with higher expression of miR-181c was similar to that of 
patients with stage III CRC who had been treated by surgical 
resection alone [40, 41]. In our study, the expression of 
miR-181c in patients with stage II CRC without recurrence 
was not significantly different from that in stage III patients 
with CRC without recurrence (P = 0.297). Moreover, 
miR-181c expression in patients with stage II CRC with 
recurrence was similar to that in stage III patients with 
recurrence (P = 0.825) [39]. Furthermore, in patients with 
lower miR-181c expression, the recurrence rate of patients 
with stage II CRC was similar to or lower than that of 
patients with stage I CRC [42].  
These findings suggest that patients with stage II CRC 
with higher miR-181c expression could be candidates for 
adjuvant chemotherapy, and that higher expression of 
miR-181c may be a useful recurrence predictor for CRC. 
Figure 1. Relapse-free survival of patients with stage II CRC. A) Kaplan–Meier method for the two groups in the training cohort using 
frozen tissue that showed both higher and lower miR-181c expressions. RFS was significantly worse for patients with higher miR-181c 
expressions than for those with lower miR-181c expressions. B) Kaplan–Meier method for the two groups in the training cohort using FFPE 
tissue that showed both higher and lower miR-181c expressions. RFS was significantly worse for patients with higher miR-181c expressions than 
for those with lower miR-181c expressions. C) Kaplan–Meier method for the two groups in the validation cohort that showed both high and low 
miR-181c expressions. RFS was significantly worse for patients with higher miR-181c expressions than for those with lower miR-181c 
expressions. The differences were analyzed by log-rank test. P < 0.05 denotes a statistically significant difference. Reprinted with permission [39]. 
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Conclusions 
Taken together, the evidence suggests that miRNAs, 
which are stable in several severe storage conditions, could 
be useful biomarkers for CRC, both in initial cancer 
screening and in recurrence prediction. 
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